Sirtex Medical is bullish about its future growth as the cancer treatment developer waits on the findings of three key clinical studies due in the first six months of 2017.
The studies are among five into liver cancer and other cancers currently underway and involving about 2,340 patients.
Chief executive Gilman Wong said the recruitment of so many patients was a "very significant" undertaking.
Mr Wong, who has been at the helm since May 2005, said there was still a lot of opportunities to enter new markets, noting that the group accounts for only a fraction of the total market.
"We have excellent long term growth potential as we are just two per cent market penetrated to date," Mr Wong said told shareholders at Tuesday's group's annual general meeting.
Sirtex reaffirmed its annual double-digit sales growth guidance.
In August, Sirtex posted a 32 per cent jump in full-year revenue to $232.5 million, and a 33 per cent jump in net profit to $53.6 million.
Sirtex shares were up 84 cents to $30.04 in a stronger Australian share market at 1257 AEDT.
